Validation of xMAP SARS-CoV-2 Multi-Antigen IgG assay in Nigeria
Open Access
- 1 April 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (4) , e0266184
Abstract
Objective: There is a need for reliable serological assays to determine accurate estimates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence. Most single target antigen assays have shown some limitations in Africa. To assess the performance of a multi-antigen assay, we evaluated a commercially available SARS-CoV-2 Multi-Antigen IgG assay for human coronavirus disease 2019 (COVID-19) in Nigeria. Methods: Validation of the xMAP SARS-CoV-2 Multi-Antigen IgG assay was carried out using well-characterized SARS-CoV-2 reverse transcription polymerase chain reactive positive (97) and pre-COVID-19 pandemic (86) plasma panels. Cross-reactivity was assessed using pre-COVID-19 pandemic plasma specimens (213) from the 2018 Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS). Results: The overall sensitivity of the xMAP SARS-CoV-2 Multi-Antigen IgG assay was 75.3% [95% CI: 65.8%– 82.8%] and specificity was 99.0% [95% CI: 96.8%– 99.7%]. The sensitivity estimate increased to 83.3% [95% CI: 70.4%– 91.3%] for specimens >14 days post-confirmation of diagnosis. However, using the NAIIS pre-pandemic specimens, the false positivity rate was 1.4% (3/213). Conclusions: Our results showed overall lower sensitivity and a comparable specificity with the manufacturer’s validation. There appears to be less cross-reactivity with NAIIS pre-pandemic COVID-19 specimens using the xMAP SARS-CoV-2 Multi-Antigen IgG assay. In-country SARS-CoV-2 serology assay validation can help guide the best choice of assays in Africa.Keywords
Funding Information
- U.S. President’s Emergency Plan for AIDS Relief (2GGH002108)
This publication has 20 references indexed in Scilit:
- Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assayJournal of Virological Methods, 2021
- Highly Sensitive and Specific Multiplex Antibody Assays To Quantify Immunoglobulins M, A, and G against SARS-CoV-2 AntigensJournal of Clinical Microbiology, 2021
- Limited Specificity of Serologic Tests for SARS-CoV-2 Antibody Detection, BeninEmerging Infectious Diseases, 2021
- High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan AfricaInternational Journal of Infectious Diseases, 2021
- Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19Nature Communications, 2020
- Cross-reactivity of SARS-CoV-2 with HIV chemiluminescent assay leading to false-positive resultsJournal of Clinical Pathology, 2020
- No serological evidence for Zika virus infection and low specificity for anti-Zika virus ELISA in malaria positive individuals among pregnant women from Madagascar in 2010PLOS ONE, 2017
- The Coronavirus Nucleocapsid Is a Multifunctional ProteinViruses, 2014
- Antibody responses to individual proteins of SARS coronavirus and their neutralization activitiesMicrobes and Infection, 2005
- Probable Inference, the Law of Succession, and Statistical InferenceJournal of the American Statistical Association, 1927